Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | SDCBP | O00560 | 4/20 | 0.45 |
| ▸ | SDC2 | P34741 | 4/20 | 0.45 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475669 | 1.00 | GAA (0.55) | GAAALDH1A1FNTAFNTBSDCBP | |
| SCHEMBL28656285 | 1.00 | GAA (0.55) | GAAALDH1A1FNTAFNTBSDCBP | |
| SCHEMBL29475702 | 0.86 | GAA (0.49) | GAAALDH1A1FNTAFNTBSDCBP | |
| SCHEMBL26347018 | 0.86 | GAA (0.49) | GAAALDH1A1FNTAFNTBSDCBP | |
| SCHEMBL30503471 | 0.86 | GAA (0.49) | GAAALDH1A1FNTAFNTBSDCBP | |
| SCHEMBL14237856 | 0.77 | GAA (0.75) | GAAALDH1A1CYP1A2CYP2C9KMT2A | |
| SCHEMBL29475643 | 0.77 | GAA (0.75) | GAAALDH1A1CYP1A2CYP2C9KMT2A | |
| SCHEMBL14237920 | 0.77 | GAA (0.75) | GAAALDH1A1CYP1A2CYP2C9KMT2A | |
| SCHEMBL23921490 | 0.77 | GAA (0.57) | GAAALDH1A1KMT2ARECQL | |
| SCHEMBL26353713 | 0.76 | GAA (0.69) | GAAALDH1A1CYP1A2CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GAA 1473/4885ALDH1A1 2172/4885FNTA 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.